Novo Nordisk A/S Investors Notified of Class Action Securities Lawsuit

Strategic Insights -

Levi & Korsinsky, LLP has notified investors in Novo Nordisk A/S (NYSE: NVO) of a class action securities lawsuit alleging securities fraud between May 7, 2025 and July 28, 2025. The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by the alleged false and misleading statements made by the Company regarding its growth potential. The lawsuit claims that Novo overstated its capability to penetrate the GLP-1 market and achieve continued growth, leading to a significant decline in the Company's stock price.

Key Takeaways:

  • The lawsuit alleges that Novo made false and misleading statements to investors about its growth potential, specifically overstating its ability to capitalize on the compounded market and penetrate the GLP-1 market.
  • The Company announced a lower sales and profit outlook on July 29, 2025, attributing the guide down to lowered growth expectations for the second half of 2025.
  • The price of Novo's common stock declined dramatically after the announcement, falling from $69.00 per share on July 28, 2025 to $53.94 per share on July 29, 2025, a decline of 21.83% in a single day.
  • The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by the alleged securities fraud.
  • Joseph E. Levi, Esq. and Ed Korsinsky, Esq. are representing the investors in the lawsuit.
  • The deadline for investors to request appointment as lead plaintiff is September 30, 2025.
  • There is no cost or obligation to participate in the lawsuit, and investors may be entitled to compensation without payment of any out-of-pocket costs or fees.

Statistics:

  • The stock price of Novo declined 21.83% in a single day on July 29, 2025.
  • The price of Novo's common stock fell from $69.00 per share on July 28, 2025 to $53.94 per share on July 29, 2025.
  • The lawsuit alleges that Novo investors suffered losses between May 7, 2025 and July 28, 2025.
  • The deadline for investors to request appointment as lead plaintiff is September 30, 2025.
  • The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by the alleged securities fraud.

Sources:

  • GlobeNewswire
  • Levi & Korsinsky, LLP
  • www.zlk.com
  • ISS Securities Class Action Services Top 50 Report